MoonLake's 'Positive' Drug Data Criticized Again for Opacity
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- MoonLake Immunotherapeutics announced "positive" results from a study of its autoimmune drug candidate, but the author argues the data presentation was marred by obtuseness that renders the word meaningless
- The STAT writer flagged this as the latest instance of a recurring pattern with MoonLake, stating the company "keeps" releasing results this way "again, and again, and again"
- Biotech companies with strong clinical trial data don't hide or obfuscate it, per the author, who frames data transparency as "a reliable predictor of future success or failure"
- Full data analysis and the specific trial details are locked behind the STAT+ paywall
Why it matters: Investors and clinicians tracking MoonLake's autoimmune drug candidate now face a third public criticism from STAT for data obfuscation accompanying "positive" announcements — a pattern the outlet says reliably signals trouble rather than progress.
Ask SkimNews
